First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report

TL;DR

A patient with ALK-rearranged lung cancer that transformed into small cell lung cancer responded well to tarlatamab treatment.

Contribution

First reported case of successful tarlatamab treatment in histologically transformed SCLC from ALK-rearranged NSCLC.

Findings

The patient showed clinical benefit from tarlatamab after progressing on multiple therapies.

Intracranial response was observed, indicating effective treatment of brain metastases.

Abstract

Small cell transformation has been described as a resistance mechanism to targeted therapy treated in patients with EGFR-mutated NSCLC and less often reported with those with other actionable oncogenic alterations, including ALK-rearranged NSCLC. Given lack of standard-of-care treatments for patients with actionable oncogenic alteration NSCLC transformed to SCLC, this remains a challenge and unmet need for treating these patients.

Here, we present a case of a patient with ALK-rearranged NSCLC with transformation to SCLC, who has progressed on several lines of therapies and successfully treated with tarlatamab to elicit and maintain clinical benefit, including intracranial response.

Figures